Inherited neurodegenerative disorder
MONDO:0024237An inherited disorder characterized by progressive degeneration and atrophy of the nervous system.
Also known as: genetic neurodegenerative disease, hereditary neurodegenerative disease, hereditary neurodegenerative disorder
808 clinical trials for this condition and its sub-types, 11 tagged with Inherited neurodegenerative disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Inherited neurodegenerative disorder
-
Frontotemporal dementia 132 trials · 178 incl. sub-types
4 sub-types
- GRN-related frontotemporal lobar degeneration with Tdp43 inclusions 6 trials · 47 incl. sub-types Sub-types →
- Behavioral variant of frontotemporal dementia 22 trials · 42 incl. sub-types Sub-types →
- Pick disease 35 trials
- Inclusion body myopathy with Paget disease of bone and frontotemporal dementia 1 trial · 3 incl. sub-types Sub-types →
-
Hereditary motor neuron disease 1 trial · 169 incl. sub-types
9 sub-types
- Spinal muscular atrophy 107 trials · 117 incl. sub-types Sub-types →
- Familial amyotrophic lateral sclerosis 2 trials · 29 incl. sub-types Sub-types →
- Lateral sclerosis 24 trials Sub-types →
- Riboflavin transporter deficiency 1 trial · 6 incl. sub-types Sub-types →
- Distal hereditary motor neuropathy 0 trials · 4 incl. sub-types Sub-types →
- ALS2-related motor neuron disease 0 trials Sub-types →
- Motor neuron disease with dementia and ophthalmoplegia 0 trials
- Neurogenic scapuloperoneal syndrome, Kaeser type 0 trials
- Prenatal-onset spinal muscular atrophy with congenital bone fractures 0 trials Sub-types →
-
Hereditary cerebellar ataxia 0 trials · 116 incl. sub-types
5 sub-types
- Autosomal recessive cerebellar ataxia 0 trials · 72 incl. sub-types Sub-types →
- Autosomal dominant cerebellar ataxia 11 trials · 33 incl. sub-types Sub-types →
- Ataxia telangiectasia 11 trials Sub-types →
- X-linked cerebellar ataxia 0 trials Sub-types →
- Ataxia-pancytopenia syndrome 0 trials
-
Huntington disease and related disorders 0 trials · 91 incl. sub-types
2 sub-types
- Huntington disease 76 trials Sub-types →
- Huntington disease-like syndrome 0 trials · 17 incl. sub-types Sub-types →
-
Progressive supranuclear palsy 74 trials · 78 incl. sub-types
4 sub-types
- Supranuclear palsy, progressive, 1 5 trials
- Atypical progressive supranuclear palsy syndrome 1 trial · 4 incl. sub-types Sub-types →
- Supranuclear palsy, progressive, 2 0 trials
- Supranuclear palsy, progressive, 3 0 trials
-
Leukodystrophy 6 trials · 72 incl. sub-types
65 sub-types
- Adrenoleukodystrophy 19 trials · 20 incl. sub-types Sub-types →
- Metachromatic leukodystrophy 20 trials Sub-types →
- Krabbe disease 15 trials Sub-types →
- Aicardi-Goutieres syndrome 9 trials Sub-types →
- Pelizaeus-Merzbacher spectrum disorder 8 trials Sub-types →
- Peroxisome biogenesis disorder 4 trials · 8 incl. sub-types Sub-types →
- Leukoencephalopathy with vanishing white matter 7 trials Sub-types →
- Canavan disease 6 trials Sub-types →
- Cerebrotendinous xanthomatosis 6 trials
- Leukoencephalopathy, diffuse hereditary, with spheroids 1 6 trials
- Alexander disease 5 trials Sub-types →
- Sjogren-Larsson syndrome 3 trials
- Leukodystrophy, demyelinating, adult-onset 0 trials · 3 incl. sub-types Sub-types →
- Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome 3 trials
- POLR-related leukodystrophy 0 trials · 2 incl. sub-types Sub-types →
- Pelizaeus-Merzbacher-like disease 1 trial · 2 incl. sub-types Sub-types →
- Hypomyelinating leukodystrophy 5 2 trials
- Hypomyelinating leukodystrophy 6 2 trials
- Hypomyelination with brain stem and spinal cord involvement and leg spasticity 2 trials
- Megalencephalic leukoencephalopathy with subcortical cysts 2 trials Sub-types →
- Sterol carrier protein 2 deficiency 1 trial
- AARS1-related leukoencephalopathy 0 trials Sub-types →
- CADDS 0 trials
- Adult-onset progressive leukoencephalopathy-early-onset deafness 0 trials
- Alkaline ceramidase 3 deficiency 0 trials
- C11orf73-related autosomal recessive hypomyelinating leukodystrophy 0 trials
- Cystic leukoencephalopathy without megalencephaly 0 trials
- Dermatoleukodystrophy 0 trials
- Early-onset calcifying leukoencephalopathy-skeletal dysplasia 0 trials
- Episodic memory defect leukoencephalopathy 0 trials
- Hereditary spastic paraplegia 2 0 trials
- Hypomyelinating leukodystrophy 10 0 trials
- Hypomyelinating leukodystrophy 12 0 trials
- Hypomyelinating leukodystrophy 13 0 trials
- Hypomyelinating leukodystrophy 9 0 trials
- Leukodystrophy, adult-onset, autosomal dominant, without amyloid angiopathy 0 trials
- Leukodystrophy, childhood-onset, remitting 0 trials
- Leukodystrophy, hypomyelinating, 14 0 trials
- Leukodystrophy, hypomyelinating, 15 0 trials
- Leukodystrophy, hypomyelinating, 16 0 trials
- Leukodystrophy, hypomyelinating, 17 0 trials
- Leukodystrophy, hypomyelinating, 18 0 trials
- Leukodystrophy, hypomyelinating, 19, transient infantile 0 trials
- Leukodystrophy, hypomyelinating, 20 0 trials
- Leukodystrophy, hypomyelinating, 22 0 trials
- Leukodystrophy, hypomyelinating, 23, with ataxia, deafness, liver dysfunction, and dilated cardiomyopathy 0 trials
- Leukodystrophy, hypomyelinating, 24 0 trials
- Leukodystrophy, hypomyelinating, 25 0 trials
- Leukodystrophy, hypomyelinating, 26, with chondrodysplasia 0 trials
- Leukodystrophy, hypomyelinating, 28 0 trials
- Leukoencephalopathy with bilateral anterior temporal lobe cysts 0 trials
- Leukoencephalopathy with mild cerebellar ataxia and white matter edema 0 trials
- Leukoencephalopathy without lacunae, adult-onset 0 trials
- Leukoencephalopathy, porphyria-related 0 trials
- Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome 0 trials
- Multiple mitochondrial dysfunctions syndrome 4 0 trials
- Neurodevelopmental disorder with microcephaly, epilepsy, and hypomyelination 0 trials
- Non-progressive predominantly posterior cavitating leukoencephalopathy with peripheral neuropathy 0 trials
- Polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly 0 trials Sub-types →
- Progressive cavitating leukoencephalopathy 0 trials
- Progressive encephalopathy with leukodystrophy due to DECR deficiency 0 trials
- Ravine syndrome 0 trials
- Ribose-5-P isomerase deficiency 0 trials
- Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy 0 trials
- Unknown leukodystrophy 0 trials
-
Familial Alzheimer disease 13 trials · 55 incl. sub-types
2 sub-types
- Early-onset autosomal dominant Alzheimer disease 31 trials · 37 incl. sub-types Sub-types →
- Alzheimer disease 2 11 trials
-
Hereditary spastic paraplegia 27 trials · 33 incl. sub-types
45 sub-types
- Complex hereditary spastic paraplegia 1 trial · 7 incl. sub-types Sub-types →
- Hereditary spastic paraplegia 50 3 trials
- Hereditary spastic paraplegia 3A 2 trials
- Hereditary spastic paraplegia 4 2 trials
- Hereditary spastic paraplegia 5A 2 trials
- Hereditary spastic paraplegia 47 1 trial
- Hereditary spastic paraplegia 51 1 trial
- Hereditary spastic paraplegia 52 1 trial
- Hereditary spastic paraplegia 7 1 trial
- ADAR-related hereditary spastic paraplegia 0 trials
- Charcot-Marie-Tooth disease type 5 0 trials
- IFIH1-related hereditary spastic paraplegia 0 trials
- RNASEH2B-related hereditary spastic paraplegia 0 trials
- Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome 0 trials
- Hereditary spastic paraplegia 10 0 trials
- Hereditary spastic paraplegia 13 0 trials
- Hereditary spastic paraplegia 14 0 trials
- Hereditary spastic paraplegia 16 0 trials
- Hereditary spastic paraplegia 2 0 trials
- Hereditary spastic paraplegia 30 0 trials Sub-types →
- Hereditary spastic paraplegia 31 0 trials
- Hereditary spastic paraplegia 33 0 trials
- Hereditary spastic paraplegia 35 0 trials
- Hereditary spastic paraplegia 48 0 trials
- Hereditary spastic paraplegia 56 0 trials
- Hereditary spastic paraplegia 6 0 trials
- Hereditary spastic paraplegia 77 0 trials
- Macrocephaly-spastic paraplegia-dysmorphism syndrome 0 trials
- Mast syndrome 0 trials
- Pure hereditary spastic paraplegia 0 trials Sub-types →
- Pure or complex hereditary spastic paraplegia 0 trials
- Spastic paraplegia 72b, autosomal recessive 0 trials
- Spastic paraplegia 79A, autosomal dominant, with ataxia 0 trials
- Spastic paraplegia 80, autosomal dominant 0 trials
- Spastic paraplegia 81, autosomal recessive 0 trials
- Spastic paraplegia 82, autosomal recessive 0 trials
- Spastic paraplegia 83, autosomal recessive 0 trials
- Spastic paraplegia 87, autosomal recessive 0 trials
- Spastic paraplegia 88, autosomal dominant 0 trials
- Spastic paraplegia 89, autosomal recessive 0 trials
- Spastic paraplegia 90A, autosomal dominant 0 trials
- Spastic paraplegia 90B, autosomal recessive 0 trials
- Spastic paraplegia 91, autosomal dominant, with or without cerebellar ataxia 0 trials
- Spastic paraplegia 92, autosomal recessive 0 trials
- Spastic paraplegia 93, autosomal recessive 0 trials
-
Hereditary optic atrophy 6 trials · 23 incl. sub-types
15 sub-types
- Leber hereditary optic neuropathy 18 trials Sub-types →
- Autosomal dominant optic atrophy 6 trials Sub-types →
- Optic atrophy 6 1 trial
- ACO2-related optic atrophy with or without extraocular features 0 trials Sub-types →
- Autosomal recessive optic atrophy, OPA7 type 0 trials
- Optic atrophy 10 with or without ataxia, intellectual disability, and seizures 0 trials
- Optic atrophy 11 0 trials
- Optic atrophy 12 0 trials
- Optic atrophy 13 with retinal and foveal abnormalities 0 trials
- Optic atrophy 14 0 trials
- Optic atrophy 15 0 trials
- Optic atrophy 16 0 trials
- Optic atrophy 2 0 trials
- Optic atrophy 4 0 trials
- Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome 0 trials
-
Neuronal ceroid lipofuscinosis 6 trials · 23 incl. sub-types
14 sub-types
- Neuronal ceroid lipofuscinosis 3 12 trials Sub-types →
- Neuronal ceroid lipofuscinosis 2 8 trials Sub-types →
- Juvenile neuronal ceroid lipofuscinosis 6 trials Sub-types →
- Ceroid lipofuscinosis, neuronal, 6A 4 trials Sub-types →
- Neuronal ceroid lipofuscinosis 7 2 trials
- Neuronal ceroid lipofuscinosis 8 1 trial · 2 incl. sub-types Sub-types →
- Neuronal ceroid lipofuscinosis 1 1 trial Sub-types →
- Neuronal ceroid lipofuscinosis 10 1 trial Sub-types →
- Neuronal ceroid lipofuscinosis 5 1 trial Sub-types →
- Adult neuronal ceroid lipofuscinosis 0 trials Sub-types →
- Ceroid lipofuscinosis, neuronal, 6B (Kufs type) 0 trials
- Congenital neuronal ceroid lipofuscinosis 0 trials
- Infantile neuronal ceroid lipofuscinosis 0 trials Sub-types →
- Progressive myoclonic epilepsy type 3 0 trials
-
Corticobasal syndrome 20 trials
-
Kennedy disease 19 trials
-
GM2 gangliosidosis 14 trials · 19 incl. sub-types
3 sub-types
- Sandhoff disease 13 trials Sub-types →
- Tay-Sachs disease 13 trials Sub-types →
- Tay-Sachs disease AB variant 0 trials
-
Frontotemporal dementia with motor neuron disease 14 trials · 19 incl. sub-types
7 sub-types
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 5 trials
- Amyotrophic lateral sclerosis type 10 3 trials
- Amyotrophic lateral sclerosis type 6 1 trial
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 0 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 0 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 0 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 6 0 trials
-
Posterior cortical atrophy 12 trials
-
Chediak-Higashi syndrome 9 trials
-
Neurodegeneration with brain iron accumulation 1 trial · 8 incl. sub-types
14 sub-types
- Neurodegeneration with brain iron accumulation 5 4 trials
- Pantothenate kinase-associated neurodegeneration 4 trials Sub-types →
- PLA2G6-associated neurodegeneration 1 trial Sub-types →
- Kufor-Rakeb syndrome 0 trials Sub-types →
- Woodhouse-Sakati syndrome 0 trials
- Aceruloplasminemia 0 trials
- Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome 0 trials
- Fatty acid hydroxylase-associated neurodegeneration 0 trials
- Neurodegeneration with brain iron accumulation 4 0 trials
- Neurodegeneration with brain iron accumulation 6 0 trials
- Neurodegeneration with brain iron accumulation 7 0 trials
- Neurodegeneration with brain iron accumulation 8 0 trials
- Neurodegeneration with brain iron accumulation 9 0 trials
- Neuroferritinopathy 0 trials
-
Inherited Creutzfeldt-Jakob disease 5 trials
-
APP-related brain and vascular amyloidosis 0 trials · 5 incl. sub-types
2 sub-types
- Alzheimer disease type 1 4 trials
- Cerebral amyloid angiopathy, APP-related 0 trials · 1 incl. sub-types Sub-types →
-
Frontotemporal dementia and/or amyotrophic lateral sclerosis 0 trials · 5 incl. sub-types
8 sub-types
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 5 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 0 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 0 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 0 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 5 0 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 6 0 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 0 trials
- Frontotemporal dementia and/or amyotrophic lateral sclerosis 8 0 trials
-
TUBB4A-related neurologic disorder 4 trials
1 sub-type
- Hypomyelinating leukodystrophy 6 2 trials
-
Fatal familial insomnia 4 trials
-
Alzheimer disease 17 1 trial
-
Alzheimer disease 18 1 trial
-
3 sub-types
-
DCTN1-related neurodegeneration 0 trials
2 sub-types
- Perry syndrome 0 trials
- Neuronopathy, distal hereditary motor, type 7B 0 trials
-
Huntington disease-like 1 0 trials
-
Huntington disease-like 2 0 trials
-
ITM2B amyloidosis 0 trials
2 sub-types
- ABri amyloidosis 0 trials
- ADan amyloidosis 0 trials
-
PEHO syndrome 0 trials
-
Angioid streaks of choroid 0 trials
-
Attenuated Chédiak-Higashi syndrome 0 trials
-
Autosomal recessive cerebral atrophy 0 trials
-
Boylan dew greco syndrome 0 trials
-
1 sub-type
-
Deafness dystonia syndrome 0 trials
-
2 sub-types
-
Ferro-cerebro-cutaneous syndrome 0 trials
-
Myoclonic cerebellar dyssynergia 0 trials
-
Striatonigral degeneration 0 trials
3 sub-types
Most studied deeper sub-types
-
Hope for genetic dementia: AL001 trial ends early
Disease control Stopped earlyThis phase 3 study tested a drug called AL001 in 119 people who carry a mutation in the progranulin gene, putting them at high risk for or already diagnosed with frontotemporal dementia. The goal was to see if AL001 could slow the worsening of memory, behavior, and language probl…
Phase 3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
Spinal injection drug targets genetic cause of ALS and dementia
Disease control Stopped earlyResearchers are testing repeated doses of an experimental drug called WVE-004 in adults who have ALS, frontotemporal dementia, or both, linked to a mutation in the C9orf72 gene. Participants receive the drug by spinal injection every 12 weeks for up to 96 weeks. The study tracks …
Phase 1/2 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Halted gene therapy study raises questions for AMN patients
Disease control Stopped earlyThis early-stage trial tested a gene therapy called SBT101 for adrenomyeloneuropathy (AMN), a rare nerve disease that causes walking difficulties. Eight adults received either the therapy or a sham procedure. The study was terminated early, so we have limited data on safety and e…
Phase 1/2 • Sponsor: SwanBio Therapeutics, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Experimental Friedreich's ataxia drug tested in kids – but trial halted early
Disease control Stopped earlyThis early-stage trial tested a drug called nomlabofusp (CTI-1601) in 18 adolescents and children with Friedreich's ataxia, a rare genetic disease that affects movement and coordination. The goal was to check safety and how the body processes the drug. However, the study was term…
Phase 1 • Sponsor: Larimar Therapeutics, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New prostate cancer combo trial ends early
Disease control Stopped earlyThis study tested a new drug called exicorilant (CORT125281) combined with enzalutamide in men with metastatic castration-resistant prostate cancer. The goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited. It involved 39…
Phase 1/2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Continued EryDex treatment studied in rare neurological disorder
Disease control Stopped earlyThis study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (A-T) who had finished a previous trial. The main goal was to monitor safety, including side effects and serious events. The study was terminated early, and it did not aim to cure the dise…
Phase 3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental drug TPN-101 tested in rare childhood brain disease
Disease control Stopped earlyThis study tested a drug called TPN-101 (censavudine) in people with Aicardi-Goutières syndrome, a rare genetic disorder that causes severe brain inflammation. The trial enrolled only 4 participants and aimed to see if the drug could reduce immune system overactivity and check fo…
Phase 2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug aims to tame hard-to-control seizures in rare mitochondrial disorders
Disease control Stopped earlyThis study tested a drug called vatiquinone in 68 people with mitochondrial disease and epilepsy that doesn't respond to standard treatments. Participants were randomly assigned to receive either vatiquinone or a placebo for 24 weeks to see if the drug could reduce the number of …
Phase 2/3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental drug shows promise for rare genetic disorder
Disease control Stopped earlyThis Phase II trial tested a drug called N-Acetyl-L-Leucine (IB1001) in 17 people with Ataxia-Telangiectasia, a rare genetic disease that affects movement and immunity. The study aimed to see if the drug could improve symptoms and slow the disease over time. The trial was termina…
Phase 2 • Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Virus therapy fails to advance in colorectal cancer trial
Disease control Stopped earlyThis study tested a new approach using a virus that attacks cancer cells (oncolytic immunotherapy) along with two standard drugs (atezolizumab and bevacizumab) in people with advanced colorectal cancer that had stopped responding to other treatments. The trial was stopped early a…
Phase 2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Hope fades: trial of Tay-Sachs drug venglustat terminated early
Disease control Stopped earlyThis Phase 3 trial tested an oral drug called venglustat in 75 adults and children with late-onset Tay-Sachs or Sandhoff disease, rare genetic disorders that cause progressive nerve damage. The drug aimed to lower toxic fat buildup in the brain and slow disease worsening. However…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy zolgensma tested in kids with SMA who can sit but not stand
Disease control Stopped earlyThis phase 1 trial tested a gene therapy called AVXS-101 (Zolgensma) in 32 children with spinal muscular atrophy (SMA) who could sit but not stand or walk. The therapy delivers a working SMN gene via a spinal injection to help improve muscle function. The study focused on safety …
Phase 1 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Neurodegenerative drug study ends early after only 17 participants
Disease control Stopped earlyThis study was designed to let people who had already taken latozinemab in an earlier study continue receiving the drug. Only 17 people took part, and the study was stopped early. The goal was to track safety and how long people stayed on treatment, not to test if the drug could …
Phase 3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Huntington's drug safety study halted early
Disease control Stopped earlyThis study aimed to see if the drug SAGE-718 is safe for people with Huntington's disease when taken over a long period. It was an open-label study, meaning everyone knew they were getting the drug. The study was terminated early, so results are limited.
Phase 3 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
ALS drug trial halted: safety data sought from 54 patients
Disease control Stopped earlyThis study tested a new drug called VRG50635 in 54 people with ALS (Lou Gehrig's disease). The main goal was to check if the drug is safe and how the body processes it. The trial was stopped early, but researchers were looking for side effects and changes in disease progression.
Phase 1 • Sponsor: Verge Genomics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental cell therapy targets deadly childhood brain cancer
Disease control Stopped earlyThis early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 particip…
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental drug zavesca tested for rare fatal brain diseases in infants
Disease control Stopped earlyThis phase 3 trial tested the drug miglustat (Zavesca) in 30 infants with Sandhoff or Tay-Sachs diseases, rare genetic disorders that destroy nerve cells. The goal was to see if the drug could reduce hospitalizations, seizures, and feeding problems while improving motor function.…
Phase 3 • Sponsor: Tehran University of Medical Sciences • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC
-
Experimental gene therapy targets Tay-Sachs and sandhoff in kids
Disease control Stopped earlyThis early-stage trial tested a gene therapy called AXO-AAV-GM2 in children with Tay-Sachs or Sandhoff disease, rare and fatal genetic brain disorders. The therapy delivers healthy genes directly into the brain and spinal fluid to try to restore a missing enzyme. The study was te…
Phase 1 • Sponsor: Terence Flotte • Aim: Disease control
Last updated Jun 26, 2026 13:03 UTC
-
Could a High-Fat diet boost brain health in early Alzheimer's?
Symptom relief Stopped earlyThis study looks at whether a ketogenic diet (high-fat, low-carb) is practical and safe for people with early-stage Alzheimer's disease over one year. The diet may provide an alternative energy source for the brain and reduce inflammation. Researchers will track diet adherence, b…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Dementia agitation drug trial halted after just 5 patients
Symptom relief Stopped earlyThis study tested a fast-dissolving film (BXCL501) placed under the tongue to quickly reduce severe agitation in older adults with dementia. The trial aimed to enroll many participants but was stopped early after only 5 people joined. Because it ended so soon, we cannot draw reli…
Phase 2 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a synthetic cannabinoid calm agitation in frontotemporal dementia?
Symptom relief Stopped earlyThis phase 2 trial tests whether nabilone, a synthetic cannabinoid, can reduce agitation in people with frontotemporal dementia (FTD). Participants receive both nabilone and a placebo in random order to compare effects. The study includes adults with behavioral variant FTD or pri…
Phase 2 • Sponsor: Simon Ducharme, MD • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Experimental drug aims to curb disinhibition in dementia patients
Symptom relief Stopped earlyThis study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated ear…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Touchscreen device aims to give voice to dementia patients
Symptom relief Stopped earlyThis study tested a personalized touchscreen device (My PATI) to help people with Alzheimer's or related dementias communicate their care preferences. The goal was to improve quality of life for both patients and their caregivers. The study was terminated early, so results are li…
Sponsor: Florida International University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New drug aimed at treating apathy in dementia patients tested
Symptom relief Stopped earlyThis study tested a drug called CVL-871 to see if it is safe and can help reduce apathy (lack of motivation or interest) in people with dementia. The trial included 41 participants with mild to moderate dementia and clinically significant apathy. The main goal was to check for si…
Phase 2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Could a Head-Zap at home boost your brain?
Symptom relief Stopped earlyThis study tested whether a gentle, non-invasive brain stimulation technique (tDCS) done at home, along with computer-based brain games, could improve thinking and language skills in people with primary progressive aphasia, mild cognitive impairment, or dementia. Participants use…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Brain scans reveal why dementia changes personality
Knowledge-focused Stopped earlyThis study investigates how Alzheimer's disease and frontotemporal dementia alter a person's sense of self and ability to understand others. Researchers will compare patients with healthy older adults using questionnaires and brain imaging. The goal is to link changes in self-awa…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Gut hormone shot aims to strengthen fragile bones in kids with muscle diseases
Knowledge-focused Stopped earlyThis study tested whether two gut hormones, GIP and GLP-2, could reduce bone breakdown in children with spinal muscular atrophy, cerebral palsy, or Duchenne muscular dystrophy who use wheelchairs. Participants received a liquid meal and then either a hormone injection or a placeb…
Sponsor: University of Copenhagen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Rare disease mystery: scientists watch AMN progress in hopes of finding a cure
Knowledge-focused Stopped earlyThis study followed 65 adult men with a rare inherited nerve disease called AMN (a form of spastic paraplegia) to understand how their symptoms change over time. Researchers collected data on walking ability and quality of life. The goal was to fill gaps in knowledge about the di…
Sponsor: SwanBio Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Gene therapy for krabbe disease: did it last?
Knowledge-focused Stopped earlyThis study follows up on children with Krabbe disease who received a one-time gene therapy infusion (FBX-101) in earlier trials. Researchers will monitor safety and measure motor skills over time. Only 2 participants are enrolled, so results are very limited.
Sponsor: Forge Biologics, Inc • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:47 UTC